Cala Health announced this week it raised $50 million in a Series C financing that will fund the market introduction of its wristwatch-like device that delivers nerve stimulation as a remedy for tremors of the hands.
New investors Novartis, Baird Capital, LifeSci Venture Partners and TriVentures participated in the fundraising round, and were joined by all of the company’s previous investors, including Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, GV—the investment arm of Google parent company Alphabet (NASDAQ: GOOG)—and Johnson & Johnson Innovation – JJDC, the venture capital arm of Johnson & Johnson (NYSE: JNJ). The… Read more »
UNDERWRITERS AND PARTNERS
